The effects of moclobemide on nocturnal sleep of depressed patients.

The effect of moclobemide, a short-acting, reversible, preferential type-A MAO inhibitor (300 mg daily in three divided doses), on the sleep of eight depressed patients was assessed by polysomnographic recordings in a 4-week therapeutic trial. Six patients showed an improvement greater than 50% on the Hamilton Depression Rating Scale. Compared to placebo, patients receiving moclobemide showed improved sleep continuity as judged by the decrease in wake time after sleep onset and total wake time, particularly during the intermediate and late stages of drug administration. Total sleep time increase was comprised of larger amounts of stage 2 NREM sleep. REM sleep latency was significantly increased and REM sleep % decreased during the drug administration period. However, in contrast to the older, non-selective and selective MAOIs, moclobemide had a mild REM sleep suppressant effect.